Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (4073)	2/11/1998 7:52:00 PM
From: scaram(o)uche	Respond to of 9719

V1: At H&Q, Craig Smith referred to "off label" more than once, and said that RPR estimates that the "market potential exceeds $100 million". Don't chide the messenger. I expect high-dose Gliadel to fade into the sunset. Was surprised to hear that, while GPI 1046 has been replaced with a more potent compound (old news), lead selection was not completed and is expected by the end of Q1. Disclaimers..... don't own GLFD or, for some strange reason, SEPR. Rick